Bio-Techne Corporation has announced the launch of Simple Plex Ultra-Sensitive Assays on its Ella automated benchtop platform, significantly enhancing the detection of neurological biomarkers in blood at femtogram concentrations. These assays, designed for research use, enable earlier and more precise identification of low-abundance proteins linked to diseases such as Alzheimer's, ALS, MS, Parkinson's Disease, and Traumatic Brain Injury. The Ella platform's automated workflow reduces manual steps and variability, delivering reliable results in under three hours and supporting high-throughput studies aimed at disease characterization and therapeutic development. These advancements have already been cited in over 1,000 peer-reviewed publications, including more than 200 focused on neurology, underscoring the platform's impact on neuroscience research.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bio-Techne Corporation published the original content used to generate this news brief on January 28, 2026, and is solely responsible for the information contained therein.